Biotechnology · Healthcare
Dr. Maria Arantxa Horga
Equibles does not estimate personal net worth.
Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVIR alertsAbout Dr. Maria Arantxa Horga
The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,593,827 for Dr. Maria Arantxa Horga in fiscal 2025, including a base salary of $523,644. Disclosed compensation is on record for 6 fiscal years. Dr. Maria Arantxa Horga has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Atea Pharmaceuticals, Inc. on September 15, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.
Dr. Maria Arantxa Horga on recent calls
“So the C-Beyond trial, our U.S. trial, we recently have data released from it, and we were very excited to see very robust efficacy with rates in 94, 95 percent with only an eight-week regimen as compared to the standard of care, which was a 12-week regimen, and this is with the attributes of what people are expecting…”
“In May, at the European Association for the Study of the Liber Congress, or ESO, four ATEA posters were presented. They included the results from the full cohort of patients involved in the Phase II study, evaluating the regimen of benifosphovir and rusevir for HCV, which are highlighted in the coming slides.”
Affiliation history
-
Atea Pharmaceuticals, Inc. (AVIR)
Proxy statement
CurrentStart not stated–present
Last confirmed April 27, 2026
Company network
Leadership on record at Atea Pharmaceuticals, Inc.
- Jean-Pierre Sommadossi CEO, Board Member
- Andrea Corcoran CFO
- Wayne Foster Chief Accounting Officer
- Arthur Kirsch Board Member
- Barbara Duncan Board Member
- Bruce Polsky Board Member
- Bruno Lucidi Board Member
- Franklin Berger Board Member
- Howard Berman Board Member
- Howard H. Berman Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $523,644 | $1,593,827 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $508,392 | $1,853,306 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $493,584 | $1,849,189 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $470,080 | $1,845,513 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $452,000 | $8,136,376 |
| 2020 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Medical Officer | $142,564 | $2,149,064 |